Training Course

Oncology Drug Development in Practice

www.congressbydesign.com/ODDP-2014

Amsterdam, The Netherlands
November 26-28, 2014

This 3-day educational program, offered by Congress by design and INC Research, teaches knowledge and skills needed by professionals in oncology drug development in the corporate and academic setting. It is the continuation of a highly successful program offered annually since 2004.

Education offered

Oncology drug development is different from drug development in other therapeutic areas. The specific features of the preclinical and clinical development of new therapeutic agents for the treatment of cancer will be addressed during this course. The course will cover the complete development process, from preclinical development, through early-phase and late-phase clinical development, to post-registration clinical studies. It will also address essentials of tumor biology, medical oncology, hemato-oncology, tumor immunology and immunotherapy as well as biostatical and regulatory issues in the development of cancer therapeutics.

Part A of the educational program also serves as a condensed one-day introduction to the field of oncology and cancer therapy, and may be booked separately.

During part B of the course, participants will practice the newly acquired knowledge in group exercises in small groups.

Schedule

The course will run for three full days. There will be an evening program on day 2, including dinner.

Wednesday, November 26

PART A

- Course introduction
- Carcinogenesis & tumor cell biology
- Oncopathology: Diagnosing cancer
- Essentials of medical oncology
- Essentials of hemato-oncology
- Tumor immunology and cancer immunotherapy

Thursday, November 27

PART B:

- Anticancer drug development: The regulatory environment
- Preclinical development of anticancer agents
- Identification and development of molecular diagnostics and biomarkers for targeted cancer therapeutics
- Phase 1 studies of single agents
- Phase 1 studies of combinations of targeted therapies
- Drug development in oncology: Global pharma and small biotech companies' perspectives (evening session with dinner)

Friday, November 28

PART B (continued):

- Late-phase clinical development, including phase 2 and 3 studies
- Biostatistics in oncology clinical trials
- Post-registration clinical studies in oncology: Aims, study designs, organizational and regulatory issues
- Closing: Take home messages & overall evaluation

Faculty

Educational themes will be elaborated by experts from leading academic research institutes and oncology-orientated drug companies, all having ample expertise and hands-on experience in cancer research, clinical oncology, or anticancer drug development.

Confirmed faculty as per May 1, 2014*:

Rob Berg, Medical Director Oncology, INC Research, Utrecht, The Netherlands (course chairman)

Ferry Eskens, Medical Oncologist, Erasmus Medical Center, Rotterdam, The Netherlands

Remond Fijneman, Geneticist, VU University Medical Center, Amsterdam, The Netherlands

Adriaan Fruijtier, Director, Regulatory Affairs, CATS Consultants, Dietmannsried, Germany

Eric Hoedemaker, Medical Director, Novartis Pharma, Arnhem, The Netherlands

Marie José Kersten, Hematologist, Academic Medical Center, Amsterdam, The Netherlands

Marinus Lobbezoo, Senior Biomedical Consultant, Congress by design, Harmelen, The Netherlands (course chairman)

Kees Melief, Professor of Immunohematology, Leiden University Medical Center, Leiden, The Netherlands

Alain van Gool, Professor and Head Radboud Center for Proteomics, Glycomics & Metabolomics, Radboud University Medical Center, Nijmegen, The Netherlands

Kate Owen, Medicine and Science Director, AstraZeneca, Macclesfield, Cheshire, UK

Eric van der Putten, Oncology Drug Development Expert, Leiderdorp, The Netherlands (also course chairman)

Paul van Diest, Professor of Pathology, University Medical Center, Utrecht, The Netherlands

Jan Vermorken, Professor of Medical Oncology, Antwerp University, Edegem, Belgium

Geraldine Vink, Senior Medical Advisor Oncology, Amgen, Breda, The Netherlands

Wouter Wijker, Biostatistician, Auxiliis Clinical Development, Budapest, Hungary

** Visit the course website for the actual list of faculty.*

Target audience

The course is intended for everyone wishing to acquire or improve his/her skills in the development of new cancer therapeutics. The education offered will be particularly useful for oncology drug development professionals in industry, the CRO environment, and academic research institutes, who recently entered the field of oncology. An understanding of the basic principles of biology and medicine at the graduate level is required for successful participation.

This is how participants rated previous ODDP courses:



Venue and hotel

The course will be held at Mercure Hotel Amsterdam City, which is only fifteen minutes from Schiphol by taxi. Schiphol Airport has frequent daily connections with most European capitals and other major cities. It can also be reached conveniently by train (Thalys) from Paris, Brussels and Antwerp.

Convenient hotel accommodation at the course venue may be booked by ODDP 2014 participants at a discounted rate during registration. Foreign participants and Dutch participants living far away are advised to book hotel accommodation at the venue to ensure presence at the course on time for the first session in the mornings. Transfers between other hotels in Amsterdam and the course venue may take a considerable amount of time.

Tuition

Category	Part A and B	Part A only	Part B only
Non-profit	€ 1,950	€ 725	€ 1,325
Corporate	€ 2,600	€ 950	€ 1,750

All fees are exclusive of VAT and do not include hotel accommodation and dinners, except the dinner on November 27. Coffee, tea, and lunches are included.

Applications

To register for the ODDP course please visit www.congressbydesign.com/oddp-2014. This will enable you to make your final booking, pay the applicable tuition, and, if desired, reserve hotel accommodation at the venue. Applications will be accepted in the order in which they are received. A maximum of 25 participants will be accepted.

About INC Research

INC Research is a therapeutically focused clinical research organization with a high-performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to us for a complete range of customized Phase I to IV programs in all therapeutic areas and patient populations. Our Trusted Process® methodology and therapeutic foresight lead customers to better-informed product development decisions, while our solid site relationships are a critical success factor in delivering clinical trial results on time and on budget. For more information www.incresearch.com.

About Congress by design

Congress by design (Cbd) is an independent, state-of-the-art PCO (professional congress organizer) serving a wide range of organizations, including universities, corporations, associations and governmental agencies. Cbd is a congress management agency with ample experience as a meeting organizer of national and international events, both small and large.

Congress by design

Course management
Congress by design
P.O. Box 77
3480 DB Harmelen
The Netherlands
Tel. +31 (0)88-089 8101
Fax +31 (0)88-089 8109
oddp@congressbydesign.com
www.congressbydesign.com/ODDP-2014